Beyond technology, regulations weigh heavily on the minds of pharma executives. Four out of 10 leaders believe regulatory ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

In an effort to combat the state’s shortage of primary care physicians, Blue Cross Blue Shield of Massachusetts is offering ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, outlines the recent shift in the patient services industry towards a hybrid hub model for ...

Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such ...